<div id="readability-page-1">PharmaCyte Biotech Inc. (NASDAQ:PMCB) shares skyrocketed 67.8% on Tuesday after the company announced it had completed the successful monetization of its stake in Femasys Inc. (NASDAQ:FEMY), significantly bolstering its liquidity. The sale is projected to lift PharmaCyte’s combined cash and marketable securities to roughly $20 million, up from $13.3 million reported as of July 31, […]</div>

PMCB

FEMY

<p>PharmaCyte Biotech Inc.（納斯達克代碼：PMCB）股價上漲 67.8%，因成功變現其在 Femasys Inc.（納斯達克代碼：FEMY）中的股份，增強了流動性。此次出售使 PharmaCyte 的現金和可交易證券增加至約 2000 萬美元，較之前的 1330 萬美元有所上升</p>

PharmaCyte Biotech 股票在成功從 Femasys 投資中獲利退出後大幅上漲